If you look at the "About the Company" section at the end of the PR it states " The Company’s Psoriasis drug candidate Prurisol completed a Phase 2 trial and the Company has since conducted a Phase 2b study, with topline results expected in 2Q2018." As mentioned the data is still presently blinded so I am guessing they are now looking at an April announcement for top line. I think the PR was a message that IPIX continues to advance towards partnership with B-OM being the likely first product to market. A secondary message is that P topline is taking longer than expected but expectations remain high that it will be a major franchise drug. I have been around for 6 years so an extra month to get game-changing results does not change my outlook. Partnership/ Partnerships could happen at any time.